Welcome to the 2020 full year and fourth quarter earnings call of United Therapeutics. We are going to have a really great call today. UT is a pulmonary hypertension Company, now becoming both a pulmonary hypertension and a pulmonary fibrosis Company.

We expect our products for these two markets to generate double-digit growth for several years to come. For example, today we report that our fourth quarter 2020 revenues grew by double-digits, about 24% from fourth quarter 2019 and even excluding a one-time 2019 operation in the distributor order patterns, revenue still grew over 10%, fourth quarter year-over-year with Tyvaso posting a 27% growth fourth quarter year-over-year and Orenitram posting a UT record 30% growth.

Let me now go into some detail on why we expect strong growth in Treprostinil patient counts to continue. Starting with our pulmonary hypertension activities, we believe organic growth from our existing three commercialized products as well as new products emerging from our pipeline will drive double-digit growth.

READ FULL ARTICLE HERE